Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
Ovarian clear cell carcinoma (OCCC) is a histological subtype of ovarian cancer that is more frequent in Asian countries (~25% of ovarian cancers) than in US/European countries (less than 10%). OCCC is refractory to conventional platinum-based chemotherapy, which is effective against high-grade sero...
Main Authors: | Kazuaki Takahashi, Masataka Takenaka, Aikou Okamoto, David D. L. Bowtell, Takashi Kohno |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/8/1769 |
Similar Items
-
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
by: Zesi Liu, et al.
Published: (2024-02-01) -
<i>CCNE1</i> Is a Putative Therapeutic Target for <i>ARID1A</i>-Mutated Ovarian Clear Cell Carcinoma
by: Naoki Kawahara, et al.
Published: (2021-05-01) -
Therapeutic Role of Synthetic Lethality in ARID1A-Deficient Malignancies
by: Kyaw Z. Hein, et al.
Published: (2024-02-01) -
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
by: Yu-Chien Lin, et al.
Published: (2020-12-01) -
The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
by: Hiu Tang, et al.
Published: (2023-04-01)